GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC

Canonical company identity and public leadership record.

NASDAQ: GALTUS

  • Source reported. 25 claims from 3 sources.
  • Not claimed by the company.
  • Eval: not assessed.
Board
10 directorsAlpha calculation. Published seats
Independence
7 of 10Alpha calculation
Committees
5
Evidence
3 sources25 published claims
Last reviewed
Freshness: current
Open conflicts
0None open
Alpha EvalNot assessed. No Eval is published for this company.

Leadership

3 claims
Leadership
PersonRoleSinceStatusEvidence
Jack W. CallicuttChief Financial OfficerCurrentSource reportedE3

Stated in the record as Jack W. Callicutt: Chief Financial Officer

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:15

Report an error
Joel LewisChief Executive Officer and PresidentCurrentSource reportedE4

Stated in the record as Joel Lewis: Chief Executive Officer and President

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:16

Report an error
Khurram Jamil, M.D.Chief Medical OfficerCurrentSource reportedE5

Stated in the record as Khurram Jamil, M.D.: Chief Medical Officer

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:17

Report an error

Board

10 claims
Board of directors
DirectorStatusSinceCommitteesEvidence
Benjamin S. Carson, Sr., M.D.Not independentNone publishedSource reportedE2

Stated in the record as Benjamin S. Carson, Sr., M.D.: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:5

Report an error
Elissa J. Schwartz, Ph.D.IndependentNone publishedSource reportedE2

Stated in the record as Elissa J. Schwartz, Ph.D.: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:6

Report an error
Gilbert F. Amelio, Ph.D.IndependentNone publishedSource reportedE2

Stated in the record as Gilbert F. Amelio, Ph.D.: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:7

Report an error
Harold H. Shlevin, Ph.D.IndependentNone publishedSource reportedE2

Stated in the record as Harold H. Shlevin, Ph.D.: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:8

Report an error
Joel LewisNot independentNone publishedSource reportedE2

Stated in the record as Joel Lewis: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:9

Report an error
Kary EldredIndependentAuditSource reportedE2

Stated in the record as Kary Eldred: Director, Audit

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:10

Report an error
Kevin D. FreemanIndependentAudit; Audit; Compensation; Nominating and Governance; Compensation; Nominating and GovernanceSource reportedE2

Stated in the record as Kevin D. Freeman: Director, Audit; Compensation; Nominating and Governance

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:11

Report an error
Marc Rubin, M.D.IndependentNone publishedSource reportedE2

Stated in the record as Marc Rubin, M.D.: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:12

Report an error
Richard A. ZordaniIndependentAudit, chair; Audit · ChairSource reportedE2

Stated in the record as Richard A. Zordani: Director, Audit · Chair

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:13

Report an error
Richard E. UihleinNot independentNone publishedSource reportedE2

Stated in the record as Richard E. Uihlein: Director

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:14

Report an error

Committees

8 claims
Committee risk allocation
CommitteeChairMembersRisks assignedEvidence
AuditRichard A. ZordaniRichard A. Zordani, Kary Eldred, Kevin D. FreemanNot described in the published recordSource reportedE6

Stated in the record as Audit: Chair Richard A. Zordani; Members Richard A. Zordani (Chair); Kary Eldred; Kevin D. Freeman

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_record:18

Report an error
Audit · ChairNot publishedRichard A. ZordaniNot described in the published record
Audit; Compensation; Nominating and GovernanceNot publishedKevin D. FreemanNot described in the published record
CompensationNot publishedKevin D. FreemanNot described in the published recordSource reportedE6

Stated in the record as Compensation: Chair not stated; Members Kevin D. Freeman

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_record:22

Report an error
Nominating and GovernanceNot publishedKevin D. FreemanNot described in the published recordSource reportedE6

Stated in the record as Nominating and Governance: Chair not stated; Members Kevin D. Freeman

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_record:24

Report an error
Committees and risk ownership: further claims
FactStated valueEvidence
Committee appointmentRichard A. Zordani: chair, AuditSource reportedE6

Stated in the record as Richard A. Zordani: chair, Audit

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_appointment:19

Report an error
Committee appointmentKary Eldred: member, AuditSource reportedE6

Stated in the record as Kary Eldred: member, Audit

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_appointment:20

Report an error
Committee appointmentKevin D. Freeman: member, AuditSource reportedE6

Stated in the record as Kevin D. Freeman: member, Audit

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_appointment:21

Report an error
Committee appointmentKevin D. Freeman: member, CompensationSource reportedE6

Stated in the record as Kevin D. Freeman: member, Compensation

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_appointment:23

Report an error
Committee appointmentKevin D. Freeman: member, Nominating and GovernanceSource reportedE6

Stated in the record as Kevin D. Freeman: member, Nominating and Governance

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:committee_appointment:25

Report an error

Authority

1 claim
Authority to act
FactStated valueValid fromEvidence
Principal executive officerJoel Lewis, Chief Executive Officer and President, from Mar 31, 2026Source reportedE4Same claim as above

Stated in the record as Joel Lewis: Chief Executive Officer and President

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:leadership_role:16

Report an error

Not in the public record: who can authorize an agent; ai agents registered by the company; delegations published.

Financial context

1 claim
Financials and market context
FactStated valueEvidence
Security listingGALT (NASDAQ)Source reportedE1

Stated in the record as GALT (NASDAQ)

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:security_listing:26

Report an error

Other published claims

3 claims
Other published claims
FactStated valueEvidence
Legal nameGALECTIN THERAPEUTICS INCSource reportedE1

Stated in the record as GALECTIN THERAPEUTICS INC

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:legal_name:1

Report an error
Entity statusPublic listing publishedSource reportedE1

Stated in the record as Public listing published

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:entity_status:3

Report an error
Published factUSSource reportedE1

Stated in the record as US

Claim ID alpha:claim:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad:published_fact:4

Report an error

Evidence

6 evidence records
Evidence ledger
RefSourceAuthoritySource dateRetrievedRightsCited by
E1Alpha canonical company public projectionCanonical identityOpen webNot recordedRights not recorded, link only4 claims
E2GALECTIN THERAPEUTICS INC DEF 14A 2025-10-22SEC proxyAuthoritative, regulatory filingRights not recorded, link only10 claims
E3GALT 10-K executive officersSEC filingAuthoritative, regulatory filingRights not recorded, link only1 claim
E4GALT 10-K executive officersSEC filingAuthoritative, regulatory filingRights not recorded, link only1 claim

No evidence record is pinned or signed yet.

Not yet in this record

These parts of a company record have no published claims yet. That is a coverage state, not a finding about the company. 1 further claim is under review.

  • Control and voting
  • Governance
  • Risk
  • AI oversight
  • Compensation

Index memberships

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of 22 Nov 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Coverage states the record reports (12)
Corporate structure
Not reviewed. Parent, subsidiary and predecessor structure explains who is governed.
Ownership
Not reviewed. Ownership and voting power determine who can influence the board.
Financials
Not reviewed. Governance-relevant financial context frames capital and audit decisions.
Compensation
Not reviewed. Pay design shows how incentives are governed.
Governance
Not reviewed. Governing documents and provisions set the rules of the enterprise.
Shareholder governance
Not reviewed. Meeting and vote records show shareholder dissent and support.
Audit
Not reviewed. Auditor, controls and restatements show assurance over reporting.
Legal
Not reviewed. Material legal and regulatory matters show enforcement exposure.
Risk
Not reviewed. Risk ownership links the board, committees, executives and controls.
Cyber
Not reviewed. Cyber and data governance is a disclosed oversight domain.
AI governance
Not reviewed. AI oversight is a differentiated Alpha governance domain.
Markets external
Not reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
Limits of this record (5)
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.

History

Version public-1

Published .

  1. CFO role recorded. Jack W. Callicutt executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
  2. CEO role recorded. Joel Lewis executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
  3. Executive appointed. Khurram Jamil, M.D. executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
  4. Director appointed. Benjamin S. Carson, Sr., M.D. seat on GALECTIN THERAPEUTICS INC, effective 2023.Effective . Recorded .
  5. Director appointed. Elissa J. Schwartz, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
  6. Director appointed. Richard A. Zordani seat on GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
  7. Committee created. Audit · Chair committee of GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
  8. Committee member added. Richard A. Zordani member of Audit · Chair, effective 2020.Effective . Recorded .
  9. Director appointed. Harold H. Shlevin, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2019.Effective . Recorded .
  10. Director appointed. Kary Eldred seat on GALECTIN THERAPEUTICS INC, effective 2018.Effective . Recorded .
  11. Committee member added. Kary Eldred member of Audit, effective 2018.Effective . Recorded .
  12. Director appointed. Joel Lewis seat on GALECTIN THERAPEUTICS INC, effective 2017.Effective . Recorded .
  13. Director appointed. Richard E. Uihlein seat on GALECTIN THERAPEUTICS INC, effective 2017.Effective . Recorded .
  14. Director appointed. Kevin D. Freeman seat on GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
  15. Director appointed. Marc Rubin, M.D. seat on GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
  16. Committee created. Audit; Compensation; Nominating and Governance committee of GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
  17. Committee member added. Kevin D. Freeman member of Audit; Compensation; Nominating and Governance, effective 2011.Effective . Recorded .
  18. Director appointed. Gilbert F. Amelio, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2009.Effective . Recorded .

About this record

Alpha ID
alpha:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad
Version
public-1:ro-d751713988987e9331980363e24189ce
Identity
Not claimed
Evidence
Source reported
Evaluation
Not assessed
Monitoring
Not monitored yet
Authority
Not published
Freshness
Current
Integrity
Not signed yet
Basis
Published company record built from public sources
Never published
Private company data: deployments, authority grants, TrustChecks, receipts, telemetry

The company can claim this record and correct or dispute any claim. Corrections are versioned and the original stays in history. A company's own statements are shown as its own and never replace the cited evidence.